Cycloset
Cycloset contains bromocriptine mesylate, a dopamine D2 receptor agonist. It is a quick-release oral tablet formulation specifically indicated for the management of type 2 diabetes. Unlike other diabetes medications, Cycloset acts on the central nervous system to help modulate morning dopaminergic activity, which is believed to improve insulin sensitivity and glucose metabolism.
Dosage by Body Weight
The standard starting dose is 0.8 mg (1 tablet) taken orally once daily within 2 hours of waking up in the morning, always with food to minimize nausea. The dosage is typically titrated weekly by adding 0.8 mg per day until a maintenance dose of 1.6 mg to 4.8 mg (2 to 6 tablets) daily is reached, based on efficacy and tolerability.
- Body Weight
- Below 5 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age.
- Body Weight
- 5-7 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age.
- Body Weight
- 8-10 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age.
- Body Weight
- 11-15 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age.
- Body Weight
- 16-20 kg
- Dose
- Not established
- Frequency
- Not recommended
- Tracking Notes
- Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age.
| Body Weight | Dose | Frequency | Tracking Notes |
|---|---|---|---|
| Below 5 kg | Not established | Not recommended | Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age. |
| 5-7 kg | Not established | Not recommended | Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age. |
| 8-10 kg | Not established | Not recommended | Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age. |
| 11-15 kg | Not established | Not recommended | Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age. |
| 16-20 kg | Not established | Not recommended | Cycloset is not indicated for pediatric use. Safety and efficacy have not been established in patients under 18 years of age. |
Formulation
Purpose
To improve glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise.
Generic Name
Bromocriptine mesylateScheduled Drug
Yes. This medicine should be supplied or used only according to applicable prescription and regulatory requirements.